These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12964168)

  • 1. A new furoxan NO-donor rabeprazole derivative and related compounds.
    Sorba G; Galli U; Cena C; Fruttero R; Gasco A; Morini G; Adami M; Coruzzi G; Brenciaglia MI; Dubini F
    Chembiochem; 2003 Sep; 4(9):899-903. PubMed ID: 12964168
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
    Garza-González E; Tijerina-Menchaca R; Pérez-Pérez GI; Bosques-Padilla FJ
    J Chemother; 2004 Dec; 16(6):612-3. PubMed ID: 15700857
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide.
    Watanabe T; Higuchi K; Tominaga K; Fujiwara Y; Arakawa T
    Drugs Exp Clin Res; 2000; 26(2):41-5. PubMed ID: 10894554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
    Kawakami Y; Akahane T; Yamaguchi M; Oana K; Takahashi Y; Okimura Y; Okabe T; Gotoh A; Katsuyama T
    Antimicrob Agents Chemother; 2000 Feb; 44(2):458-61. PubMed ID: 10639386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.
    Tsutsui N; Taneike I; Ohara T; Goshi S; Kojio S; Iwakura N; Matsumaru H; Wakisaka-Saito N; Zhang HM; Yamamoto T
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3069-73. PubMed ID: 11036024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
    Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T
    Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitory activities of lansoprazole against respiration in Helicobacter pylori.
    Nagata K; Sone N; Tamura T
    Antimicrob Agents Chemother; 2001 May; 45(5):1522-7. PubMed ID: 11302821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
    Vasil'ev IuB
    Eksp Klin Gastroenterol; 2004; (3):14-8, 102. PubMed ID: 15560394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiulcer activity of furoxanopyrimidine derivatives].
    Kaminka ME; Kalinkina MA; Pushkina TV; Tupikina SM; Riabova OB; Makarov VA; Granik VG
    Eksp Klin Farmakol; 2004; 67(3):30-3. PubMed ID: 15341064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antiulcer activity of chromanone fraction from Calophyllum brasiliesnse Camb.
    Lemos LM; Martins TB; Tanajura GH; Gazoni VF; Bonaldo J; Strada CL; Silva MG; Dall'oglio EL; de Sousa Júnior PT; Martins DT
    J Ethnopharmacol; 2012 May; 141(1):432-9. PubMed ID: 22425905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.
    Buonsanti MF; Bertinaria M; Stilo AD; Cena C; Fruttero R; Gasco A
    J Med Chem; 2007 Oct; 50(20):5003-11. PubMed ID: 17845020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
    Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Fujioka T; Kodama M; Abe T; Sato S; Arita T
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):262-7. PubMed ID: 16460484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and synthesis of potential impurities of rabeprazole sodium.
    Pingili RR; Jambula MR; Ganta MR; Ghanta MR; Sajja E; Sundaram V; Boluggdu VB
    Pharmazie; 2005 Nov; 60(11):814-8. PubMed ID: 16320941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.
    Del Grosso E; Boschi D; Lazzarato L; Cena C; Di Stilo A; Fruttero R; Moro S; Gasco A
    Chem Biodivers; 2005 Jul; 2(7):886-900. PubMed ID: 17193179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization.
    López GV; Blanco F; Hernández P; Ferreira A; Piro OE; Batthyány C; González M; Rubbo H; Cerecetto H
    Bioorg Med Chem; 2007 Sep; 15(18):6262-72. PubMed ID: 17627828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
    Dtsch Med Wochenschr; 1998 Nov; 123(47 Suppl):1-4. PubMed ID: 9856116
    [No Abstract]   [Full Text] [Related]  

  • 19. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.